Abstracts - PAGE Meeting (Population Approach Group Europe)

Abstracts (43)

I-002Kimberly Adams

Physiologically-Based Pharmacokinetic Modeling of Extended-Release MK-2048 Formulations for HIV Pre-Exposure Prophylaxis in Non-Human Primates

Wednesday 10:20-11:50

I-009Magali Amiel

Physiologically Based Pharmacokinetic modelling of the Drug-Drug Interaction between Ivacaftor and Lefamulin in Cystic Fibrosis patients

Wednesday 10:20-11:50

I-010Karkhanis Aneesh

A PBPK model of 4β-hydroxycholesterol, an endogenous biomarker for hepatic CYP3A activity.

Wednesday 10:20-11:50

I-028Salih Benamara

Development of a PBPK model to predict monoclonal antibody pharmacokinetics and bioavailability following subcutaneous administration

Wednesday 10:20-11:50

I-051Zhihai Cao

Evaluating Drug Interactions Between Ritonavir and Hydrocodone: Implications From Physiologically Based Pharmacokinetic Simulation

Wednesday 10:20-11:50

I-053Adriana Castiñeiras

Population analysis of the in vivo pharmacokinetic characteristics of a letrozole sustained delivery formulation in Beagle dogs

Wednesday 10:20-11:50

I-060Wenjun Chen

Physiologically based pharmacokinetic modeling of TLL-018 for prediction of human pharmacokinetics and in vitro-in vivo extrapolation

Wednesday 10:20-11:50

I-063Marylore Chenel

Physiologically-based pharmacokinetic (PBPK) modeling to predict disease effects on 5-flucytosine pharmacokinetics (PK) in the context of a switch from an immediate release (IR) to a sustained release (SR) formulation in the treatment of cryptococcal meningoencephalitis.

Wednesday 10:20-11:50

I-069Léa COMIN

Modelling the whole-body pharmacokinetics (WBPK) of radiolabeled glyburide in healthy volunteers

Wednesday 10:20-11:50

I-071Bárbara Costa

Pharmacokinetic Simulation Study: Exploring Lamotrigine’s Impact Across Diverse Patient Populations

Wednesday 10:20-11:50

I-091Ricardo Diaz de Leon Ortega

Modelling and simulation of the effect of a permeability enhancer on the absorption of a poorly permeable compound

Wednesday 10:20-11:50

I-093Aris Dokoumetzidis

Extrapolation of lung pharmacokinetics of antitubercular drugs from preclinical species to humans using PBPK modeling

Wednesday 10:20-11:50

I-100Xiaoqing Fan

A Whole-body Mechanistic Physiologically-based Pharmacokinetic Modeling of Intravenous Iron

Wednesday 10:20-11:50

I-107Denise Feick

How can we inform human intestinal permeability with Caco-2 permeability using PK-Sim®?

Wednesday 10:20-11:50

I-114Laura Fuhr

Physiologically based pharmacokinetic modeling of amitriptyline and its active metabolite nortriptyline to investigate CYP2D6 and CYP2C19 mediated drug-drug and drug-gene interactions

Wednesday 10:20-11:50

II-014Sandra Grañana Castillo

Nintedanib physiologically based pharmacokinetic (PBPK) model to predict drug-drug interactions

Wednesday 15:20-16:50

II-024Jeongmin Ha

Physiologically based Pharmacokinetic and Pharmacodynamic modeling of Enzalutamide and N-desmethyl enzalutamide

Wednesday 15:20-16:50

II-047Miao-Chan Huang

Application of physiologically-based kinetic (PBK) modeling in revealing the role of the bile-salt efflux pump (BSEP) in bosentan-induced cholestasis

Wednesday 15:20-16:50

II-055Ravi Kumar Jairam

Systemic and ocular physiologically based pharmacokinetic models for protein therapeutics in rabbits

Wednesday 15:20-16:50

II-057Masoud Jamei

Same Dissolution Profile – Different Virtual Bioequivalence (VBE) Outcome! Input-Dependent Propagation of Between Subject Variability (BSV) in Gut Physiology to Dissolution and VBE

Wednesday 15:20-16:50

II-082Christina Kovar

A Physiologically Based Pharmacokinetic Model of Atorvastatin Acid Predicting CYP3A4 and OATP1B Drug–Drug Interactions

Wednesday 15:20-16:50

II-088Jonas Langeraert

Small molecule drug absorption in inflammatory bowel disease and current implementation in PBPK models.

Wednesday 15:20-16:50

II-089Emilie Langeskov

WB-PBPK-PD Modeling for Pharmacokinetics and Pharmacodynamics of GalNAc-Conjugated siRNAs

Wednesday 15:20-16:50

II-111Helena Loer

Unraveling the CYP2D6 Drug-Drug-Gene Interaction Network: A Comprehensive PBPK Analysis of Key Substrates and Inhibitors

Wednesday 15:20-16:50

II-112Ioannis Loisios-Konstantinidis

Physiologically based pharmacokinetic modeling and simulations to characterize the effect of cyclodextrins on the exposure of asciminib in lieu of clinical trials

Wednesday 15:20-16:50

II-113Orphélie Lootens

Unlocking Diversity: Towards a Comprehensive Framework for Physiologically Based Pharmacokinetic Population Qualification in Sub Saharan Africa

Wednesday 15:20-16:50

III-012Fatima Zahra Marok

Parent-Metabolite Physiologically Based Pharmacokinetic Modeling of Mirtazapine during Drug-Drug- and Drug-Gene-Interactions

Thursday 09:50-11:20

III-025Sarang Mishra

PBPK modelling based estimation of safe, and effective Molnupiravir doses for pediatric subpopulations against SARS-CoV-2

Thursday 09:50-11:20

III-043Chen Ning

Physiologically based pharmacokinetic modeling and simulation of a promising novel antiplatelet drug vicagrel and its metabolites

Thursday 09:50-11:20

III-045Pär Nordell

Predicting in vivo disposition of OATP substrates from in vitro kinetics using mechanistic PBPK modelling

Thursday 09:50-11:20

III-050Marije Otto

Characterization of absorption kinetics of oral esketamine in healthy volunteers

Thursday 09:50-11:20

III-053Agustos Cetin Ozbey

PBPK modeling based clinical dose adaptation in liver cirrhosis patients for seven CYP and UGT enzyme substrates

Thursday 09:50-11:20

III-058Madison Parrot

A Minimal PBPK Model to Predict Biodistribution of Silica Nanoparticles in Mice

Thursday 09:50-11:20

III-067Sara Peribanez

A physiologically-based pharmacokinetic model to predict systemic and organ exposure for colorectal cancer drugs in clinical settings

Thursday 09:50-11:20

III-085Javier Reig-López

Assessment of bioequivalence outcomes of oral formulations containing racemic ibuprofen through a chiral physiologically-based pharmacokinetic model

Thursday 09:50-11:20

III-096Donnia Robins

Elucidating parametric first and second-order effects in PBPK models for special scenarios using a GSA-based approach

Thursday 09:50-11:20

III-098Karine Rodriguez-Fernandez

Estimation of a sensitive range of dose-adjusted FaSSIF solubility to predict the food effect on BCS II/IV drugs

Thursday 09:50-11:20

III-102Karen Rowland Yeo

Relative impact of CYP2D6 phenotype, physiological changes and hepatic extraction ratio on drug exposure during pregnancy

Thursday 09:50-11:20

IV-016Felix Stader

Physiologically based pharmacokinetic modelling to predict the concentration-time profile of an antibody-drug conjugate and hepatic and renal impairment.

Thursday 15:00-16:30

IV-061Daan van Valkengoed

Reliability of in vitro data for the mechanistic prediction of brain extracellular fluid pharmacokinetics of P-glycoprotein substrates in vivo; are we scaling correctly?

Thursday 15:00-16:30

IV-076Paul Vrenken

Development of a novel open-source Physiology-Based Biopharmaceutics Modelling (PBBM) framework using the Open System Pharmacology suite

Thursday 15:00-16:30

IV-083Haini Wen

Translational physiologically based pharmacokinetic modeling to predict human pulmonary kinetics after inhalation

Thursday 15:00-16:30

IV-110Xiaonan Zhang

Assessing the Effect of Pneumonia on Tigecycline Lung Exposure Using Physiological-Based Pharmacokinetic Modelling

Thursday 15:00-16:30